In an increasingly interconnected world, pharmaceutical companies must balance global strategies with local execution to achieve launch success. This session will explore the challenges and opportunities of harmonizing global and local efforts to optimize market impact.

• Aligning global strategies with local market needs to ensure relevance and maximize impact.

• Leveraging local insights to tailor launch tactics and address specific regulatory and market requirements.

• Addressing differences in strategy between regions, countries & overcoming related challenges.

Enrico Magnani

Chief Strategy Officer
Helsinn Group

See Bio

Navigating the complexities of pricing is crucial for a successful pharmaceutical product launch. This session will delve into innovative pricing strategies that balance profitability with market accessibility, ensuring a competitive edge in diverse markets.

• Conducting comprehensive market analysis to set optimal entry prices that reflect local economic conditions.

• Implementing value-based pricing models to demonstrate the cost-effectiveness and therapeutic benefits of new treatments.

• Engaging with stakeholders early to align pricing strategies with payer expectations and reimbursement landscapes.

Successfully navigating regulatory landscapes is essential for the timely and compliant launch of pharmaceutical products. This session will explore strategies to address regulatory hurdles, ensuring smoother market entry and sustained success.

• Engaging with regulatory bodies early to align expectations and streamline approval processes.

• Developing robust compliance frameworks to meet diverse regulatory requirements across global markets.

• Utilizing advanced technologies and data analytics to anticipate and mitigate regulatory risks.

Topic Suggestion, Slot Reserved for Sponsor Partner

Oncology launches are often at the forefront of innovation due to the high unmet need and intense implementation dynamics. This session delves into the specificities of oncology launches and explores what other therapeutic areas can learn from this, focusing on strategic and operational excellence to drive successful launches across the board.

• Integrating medical affairs strategically to enhance therapeutic area-specific launch effectiveness.

• Applying oncology’s rigorous execution and strategic development practices to other therapeutic areas.

• Embracing innovative thinking from oncology to meet high unmet needs and drive change.

Effective pre-launch planning goes beyond product readiness; current best standard of care provided by health systems must be maximised through optimised referral paths and access to current best standard of care. Only then is unmet need identified and innovative medicine contribution clarified. Target Population Outputs (TPOs) are short-term measures of health system effectiveness, and thus market readiness and market size. They are common units of value to both public and private health system stakeholders being utilisable for both population health and business forecasting. This enables tactical focus and opens doors for early investment sharing with health systems through strategic public-private partnerships. TPOs bring:

• Prioritisation: Deliver cross-functional clarity on tactical prioritisation accountable to tangible external impact linked to business forecast assumptions.

• Course correction: Directs useful activity metric and KPI development directly linked to business goals enabling effective impact analysis and course correction.

• Partnerships: Facilitates early collaboration with healthcare systems stakeholders to achieve common goals by sharing tactics and reducing investment costs.

Troels Sorensen

Global Head Clinical Practice
Boehringer Ingelheim

See Bio

This session explores crucial strategies for optimizing supply chain operations to ensure seamless pharmaceutical product launches. As the industry evolves, efficient supply chain management becomes increasingly vital for timely market entry and sustained commercial success.

• Implementing agile supply chain frameworks to enhance flexibility and responsiveness.

• Leveraging advanced forecasting and demand planning technologies for accurate inventory management.

• Forging strategic partnerships with logistics providers to ensure reliable distribution channels.

This panel delves into critical strategies for improving patient access and support throughout the pharmaceutical product lifecycle. Ensuring patient-centric approaches not only enhances market penetration but also fosters sustainable patient engagement and adherence.

• Developing comprehensive patient access programs tailored to diverse patient demographics and needs.

• Utilizing digital health technologies to enhance patient education and remote support capabilities.

• Collaborating closely with healthcare providers and advocacy groups to streamline access pathways and support services.

Maria B. Petersen

Senior Global Product Manager
Novo Nordisk

See Bio

In today’s digital environment, capturing and maintaining attention is increasingly challenging. With almost 4 launches under her belt, Angeliki will delve into strategies for creating meaningful differentiation through compelling narratives and incremental value, ensuring your launch efforts resonate deeply with your audience.

• Developing compelling human narratives that deliver innovative, emotive content that deeply connects with customers to creative meaningful belief and behaviour change.

• Building a strong brand story and narrative that stands out in a crowded competitive landscape.

• Principles that Galderma leverage to deliver content that is linked to the customer’s critical thinking and actions.

Angeliki Nikoli

Global Head of Neuromodulators Franchise
Galderma

See Bio

This panel delves into leveraging real-world evidence (RWE) to enhance pharmaceutical launch strategies, ensuring insights from actual clinical practice inform decision-making. Exploring how RWE can drive evidence-based market access and optimize patient outcomes post-launch. Investing in reskilling and upskilling programs to empower employees for future roles in AI-driven environments.

• Incorporating RWE to validate efficacy and safety in diverse patient populations.

• Using RWE to demonstrate value and differentiate in competitive markets.

• Collaborating with stakeholders to utilize RWE for regulatory and payer negotiations.

for successful pharmaceutical launches. This session explores how to effectively execute and continuously optimize omnichannel strategies in this post-covid digital era across clinical, medical, strategic, and commercial dimensions, ensuring seamless integration from trial data to prescription. Attendees will gain insights into navigating the complexities of engaging healthcare professionals and patients in a compliant, impactful, practical and cross-functional way.

• Integrated Collaboration: Aligning clinical, medical, and commercial teams to build cohesive omnichannel strategies that drive prescriptions.

• Data-Driven Adjustments: Using real-time data to continuously refine and adjust omnichannel efforts for maximum impact.

• Strategic Execution: Implementing compliant, targeted strategies that link KOL insights and trial data with commercial goals, enhancing physician engagement and patient outcomes.

Michelle Elise Reding

Obesity Brand Lead
Novo Nordisk

See Bio

This session delves into the critical strategies for successfully launching cutting-edge cell and gene therapies, emphasizing innovative approaches amidst regulatory complexities and market dynamics.

Gain insights into achieving optimal market entry and patient access for transformative therapies.

• Establishing early engagement with regulators to streamline approval processes.

• Developing robust patient access programs to navigate reimbursement challenges.

• Leveraging partnerships for manufacturing scalability and supply chain readiness.

Launching a pharmaceutical product globally isn’t a one-size-fits-all endeavour. Different countries present unique challenges and opportunities that can make or break your launch strategy. In this session, Margarita will delve into how to effectively navigate various country archetypes, ensuring that your launch is not only successful in top markets but also equitable and impactful across the globe.

• Tailoring Strategies: Aligning launch tactics to specific country archetypes beyond GDP—consider reimbursement, regulations, and market dynamics.

• Leveraging Public Data: Utilizing accessible data to accurately categorize and understand each country’s unique market landscape.

• Adapting for Equity: Implementing strategies that address health equity, ensuring global reach without compromising on local impact.

Margarita Saakova

Global Head of Launch
Alexion Pharmaceuticals

See Bio

Explore innovative strategies and emerging trends shaping the future of pharmaceutical launch excellence for sustainable success in a dynamic healthcare landscape.

• Implementing digital technologies and advanced analytics for enhanced market insights.

• Developing adaptive launch strategies to address evolving regulatory and market challenges.

• Fostering patient-centric approaches and partnerships for long-term market impact.